106 related articles for article (PubMed ID: 19440016)
1. Significance of serum calcitonin gene-related peptide levels in prostate cancer patients receiving hormonal therapy.
Suzuki K; Kobayashi Y; Morita T
Urol Int; 2009; 82(3):291-5. PubMed ID: 19440016
[TBL] [Abstract][Full Text] [Related]
2. Serum calcitonin gene-related peptide levels in untreated prostate cancer patients.
Suzuki K; Kobayashi Y; Morita T
Int J Urol; 2006 Jun; 13(6):781-4. PubMed ID: 16834660
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
4. Glucose intolerance during hormonal therapy for prostate cancer.
Suzuki K; Nukui A; Hara Y; Morita T
Prostate Cancer Prostatic Dis; 2007; 10(4):384-7. PubMed ID: 17486109
[TBL] [Abstract][Full Text] [Related]
5. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
[TBL] [Abstract][Full Text] [Related]
6. Urinary excretion of calcitonin gene-related peptide in males with hot flushes after castration for carcinoma of the prostate.
Wyon Y; Spetz AC; Hammar M; Theodorsson E; Varenhorst E
Scand J Urol Nephrol; 2001 Apr; 35(2):92-6. PubMed ID: 11411665
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan.
Sasaki T; Nakamura K; Ogawa K; Onishi H; Okamoto A; Koizumi M; Shioyama Y; Mitsumori M; Teshima T;
BJU Int; 2009 Nov; 104(10):1462-6. PubMed ID: 19522869
[TBL] [Abstract][Full Text] [Related]
8. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer.
Nagakawa O; Yamagishi T; Akashi T; Nagaike K; Fuse H
Prostate; 2006 Apr; 66(5):447-52. PubMed ID: 16353247
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer.
Hessels D; van Gils MP; van Hooij O; Jannink SA; Witjes JA; Verhaegh GW; Schalken JA
Prostate; 2010 Jan; 70(1):10-6. PubMed ID: 19708043
[TBL] [Abstract][Full Text] [Related]
10. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker.
Hayashi T; Matsubara A; Ohara S; Mita K; Hasegawa Y; Usui T; Arihiro K; Norimura S; Sentani K; Oue N; Yasui W
Oncol Rep; 2009 Jan; 21(1):95-100. PubMed ID: 19082448
[TBL] [Abstract][Full Text] [Related]
12. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
13. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
14. CGRP and ET-1 plasma levels in normal subjects.
Parlapiano C; Paoletti V; Campana E; Giovanniello T; Pantone P; Labbadia G; Califano F; Donnarumma L; Musca A
Eur Rev Med Pharmacol Sci; 1999; 3(3):139-41. PubMed ID: 10827818
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin gene-related peptide in cervicogenic headache.
Frese A; Schilgen M; Edvinsson L; Frandsen E; Evers S
Cephalalgia; 2005 Sep; 25(9):700-3. PubMed ID: 16109051
[TBL] [Abstract][Full Text] [Related]
16. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentration of selected neuropeptides in patients suffering from psoriasis.
Reich A; Orda A; Wiśnicka B; Szepietowski JC
Exp Dermatol; 2007 May; 16(5):421-8. PubMed ID: 17437485
[TBL] [Abstract][Full Text] [Related]
18. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
Greil S; Robinson EA; Singal B; Kleer E
Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment total testosterone levels in patients with prostate cancer in the past two decades in Japan.
Sekine Y; Ito K; Yamamoto T; Nakazato H; Shibata Y; Hatori M; Suzuki K
Cancer Detect Prev; 2007; 31(2):149-53. PubMed ID: 17418977
[TBL] [Abstract][Full Text] [Related]
20. Serum and tissue selenium levels in gastric cancer patients and correlation with CEA.
Charalabopoulos K; Kotsalos A; Batistatou A; Charalabopoulos A; Peschos D; Vezyraki P; Kalfakakou V; Metsios A; Charalampopoulos A; Macheras A; Agnantis N; Evangelou A
Anticancer Res; 2009 Aug; 29(8):3465-7. PubMed ID: 19661375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
